Featured Studies

If you struggle with psoriatic arthritis, you may qualify for the IZAR Study. The study is evaluating an investigational medication that is designed to help alleviate symptoms of psoriatic arthritis.

We are currently conducting an online survey to understand patient preferences and considerations for the treatment of Psoriasis. 

• The survey will only take 5-10 minutes of your time
• You can take this survey using your smart phone or computer by clicking the button below.

Adults with psoriatic disease are invited to take part in the 2025 NPF Advocacy survey focused on insurance coverage, medication access, and healthcare experiences. Your insights will help us better understand how coverage and cost influence treatment decisions. Participants will be compensated for their time.

If you’re living with moderate to severe psoriasis, you may qualify for the EVERLAST-A Study. The study is evaluating an investigational medication to see if it can help relieve the pain, itch, skin irritation, and other symptoms caused by psoriasis.

There could be a clearer future for psoriasis, and we could help shape it together. The Latitude Atlas Study is comparing an investigational oral treatment, zasocitinib, to an approved oral treatment, deucravacitinib.

• No placebo
• No health insurance required

The University of Michigan is enrolling for a 2-year psoriasis treatment study to understand changes in people’s skin when using the study drug.

• If eligible, bimekizumab is provided at no charge
• Biopsies and blood draws required
• Current therapy must be discontinued
• Compensation provided